JP6581774B2 - 非天然アミノ酸結合ドラスタチン誘導体を含有する化合物またはその化合物の溶媒和物、およびドラスタチンアナログを誘導体化するための方法 - Google Patents

非天然アミノ酸結合ドラスタチン誘導体を含有する化合物またはその化合物の溶媒和物、およびドラスタチンアナログを誘導体化するための方法 Download PDF

Info

Publication number
JP6581774B2
JP6581774B2 JP2014512124A JP2014512124A JP6581774B2 JP 6581774 B2 JP6581774 B2 JP 6581774B2 JP 2014512124 A JP2014512124 A JP 2014512124A JP 2014512124 A JP2014512124 A JP 2014512124A JP 6581774 B2 JP6581774 B2 JP 6581774B2
Authority
JP
Japan
Prior art keywords
alkylene
substituted
alkyl
amino acid
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014512124A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014516050A (ja
Inventor
ミャオ，ツェンウェイ
アトキンソン，カイル，シー．
ビロック，サンドラ
バス，ティモシー
ニール，メリッサ
クレイノフ，ベイディム
マースデン，ロビン
ピンクスタッフ，ジェイソン
スキッドモア，リリアン
サン，イング
スツィードリック，アニエスカ
ド バレンタ，デリア ラニーニャ ロペス
ド バレンタ，デリア ラニーニャ ロペス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ambrx Inc
Original Assignee
Ambrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47259774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6581774(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ambrx Inc filed Critical Ambrx Inc
Publication of JP2014516050A publication Critical patent/JP2014516050A/ja
Application granted granted Critical
Publication of JP6581774B2 publication Critical patent/JP6581774B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from kidney or bladder cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compression Of Band Width Or Redundancy In Fax (AREA)
  • Polyamides (AREA)
JP2014512124A 2011-05-27 2012-05-24 非天然アミノ酸結合ドラスタチン誘導体を含有する化合物またはその化合物の溶媒和物、およびドラスタチンアナログを誘導体化するための方法 Active JP6581774B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161491146P 2011-05-27 2011-05-27
US61/491,146 2011-05-27
PCT/US2012/039472 WO2012166560A1 (en) 2011-05-27 2012-05-24 Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018026159A Division JP6781721B2 (ja) 2011-05-27 2018-02-16 非天然アミノ酸結合ドラスタチン誘導体を含有する組成物、それを用いた方法、およびその使用

Publications (2)

Publication Number Publication Date
JP2014516050A JP2014516050A (ja) 2014-07-07
JP6581774B2 true JP6581774B2 (ja) 2019-09-25

Family

ID=47259774

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2014512124A Active JP6581774B2 (ja) 2011-05-27 2012-05-24 非天然アミノ酸結合ドラスタチン誘導体を含有する化合物またはその化合物の溶媒和物、およびドラスタチンアナログを誘導体化するための方法
JP2018026159A Active JP6781721B2 (ja) 2011-05-27 2018-02-16 非天然アミノ酸結合ドラスタチン誘導体を含有する組成物、それを用いた方法、およびその使用
JP2020097905A Pending JP2020147587A (ja) 2011-05-27 2020-06-04 非天然アミノ酸結合ドラスタチン誘導体を含有する組成物、それを用いた方法、およびその使用
JP2022166871A Active JP7638942B2 (ja) 2011-05-27 2022-10-18 非天然アミノ酸結合ドラスタチン誘導体を含有する組成物、それを用いた方法、およびその使用
JP2024154766A Pending JP2024170587A (ja) 2011-05-27 2024-09-09 非天然アミノ酸結合ドラスタチン誘導体を含有する組成物、それを用いた方法、およびその使用

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018026159A Active JP6781721B2 (ja) 2011-05-27 2018-02-16 非天然アミノ酸結合ドラスタチン誘導体を含有する組成物、それを用いた方法、およびその使用
JP2020097905A Pending JP2020147587A (ja) 2011-05-27 2020-06-04 非天然アミノ酸結合ドラスタチン誘導体を含有する組成物、それを用いた方法、およびその使用
JP2022166871A Active JP7638942B2 (ja) 2011-05-27 2022-10-18 非天然アミノ酸結合ドラスタチン誘導体を含有する組成物、それを用いた方法、およびその使用
JP2024154766A Pending JP2024170587A (ja) 2011-05-27 2024-09-09 非天然アミノ酸結合ドラスタチン誘導体を含有する組成物、それを用いた方法、およびその使用

Country Status (23)

Country Link
US (4) US9796754B2 (https=)
EP (2) EP2714684B1 (https=)
JP (5) JP6581774B2 (https=)
KR (4) KR102356286B1 (https=)
CN (4) CN110078788B (https=)
AU (4) AU2012262560B2 (https=)
BR (1) BR112013030372A2 (https=)
CA (1) CA2837586C (https=)
CL (1) CL2013003406A1 (https=)
CO (1) CO6811816A2 (https=)
CR (1) CR20130667A (https=)
DK (1) DK2714684T3 (https=)
EA (1) EA201391756A1 (https=)
EC (1) ECSP13013115A (https=)
ES (1) ES2690993T3 (https=)
GT (1) GT201300295A (https=)
IL (3) IL229505A (https=)
MX (1) MX359217B (https=)
NI (1) NI201300130A (https=)
PE (1) PE20140784A1 (https=)
PH (1) PH12013502461A1 (https=)
WO (1) WO2012166560A1 (https=)
ZA (1) ZA201309654B (https=)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA030886B1 (ru) 2010-08-17 2018-10-31 Амбркс, Инк. Модифицированные полипептиды релаксина, содержащие некодируемую в природе аминокислоту, связанную с полимером, и их применение
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
KR102356286B1 (ko) 2011-05-27 2022-02-08 암브룩스, 인코포레이티드 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
CN110078789A (zh) * 2011-05-27 2019-08-02 Ambrx 公司 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途
US20130190248A1 (en) * 2011-07-26 2013-07-25 Agensys, Inc. Substituted peptide analogs
CN104640572B (zh) 2012-05-15 2018-04-27 索伦托医疗有限公司 药物偶联物，偶联方法，及其用途
CN108727466B (zh) * 2012-06-07 2023-04-28 Ambrx公司 前列腺特异性膜抗原抗体药物结合物
KR102190832B1 (ko) 2012-06-19 2020-12-15 암브룩스, 인코포레이티드 항cd70 항체 약물 컨쥬게이트
WO2014093379A1 (en) 2012-12-10 2014-06-19 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
CN105283201B (zh) 2013-03-14 2019-08-02 斯克利普斯研究所 靶向剂抗体偶联物及其用途
EP2968591A1 (en) * 2013-03-15 2016-01-20 Novartis AG Cell proliferation inhibitors and conjugates thereof
HK1220626A1 (zh) 2013-03-15 2017-05-12 The Centre For Drug Research And Development 具细胞毒性和抗有丝分裂的化合物以及其使用方法
FR3005051A1 (fr) * 2013-04-25 2014-10-31 Pf Medicament Derives de la dolastatine 10 et d'auristatines
PL2991683T3 (pl) 2013-05-02 2020-03-31 Glykos Finland Oy Koniugaty glikoproteiny lub glikanu z toksycznym ładunkiem
NZ758049A (en) 2013-10-15 2024-03-22 Seagen Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
AU2014337317A1 (en) 2013-10-15 2016-09-15 Sorrento Therapeutics Inc. Drug-conjugates with a targeting molecule and two different drugs
CN105829349B (zh) 2013-10-15 2023-02-03 斯克利普斯研究所 肽嵌合抗原受体t细胞开关和其用途
CN103665104B (zh) * 2013-12-09 2015-05-20 天津市康信医药科技有限公司 一种mmaf中间体五肽的合成方法
JP6636925B2 (ja) 2013-12-17 2020-01-29 ノバルティス アーゲー 細胞障害性ペプチドおよびその抱合体
WO2015095953A1 (en) 2013-12-27 2015-07-02 The Centre For Drug Research And Development Sulfonamide-containing linkage systems for drug conjugates
HRP20190888T8 (hr) 2014-04-25 2019-10-04 Pierre Fabre Médicament Konjugat antitijela za igf-1r i lijeka i njegova upotreba u liječenju karcinoma
HUE047952T2 (hu) 2014-04-25 2020-05-28 Pf Medicament Ellenanyag-drog konjugátum és alkalmazása rák kezelésében történõ alkalmazásra
CA2951368A1 (en) 2014-06-13 2015-12-17 Novartis Ag Auristatin derivatives and conjugates thereof
EP3160513B1 (en) 2014-06-30 2020-02-12 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
ES2905569T3 (es) 2014-09-17 2022-04-11 Zymeworks Inc Compuestos citotóxicos y antimitóticos y métodos para utilizarlos
AU2015358532C1 (en) * 2014-12-03 2020-10-29 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
EP3250238B1 (en) 2015-01-28 2022-06-01 Sorrento Therapeutics, Inc. Antibody drug conjugates
EP3268038B1 (en) 2015-03-09 2021-05-05 Agensys, Inc. Antibody drug conjugates (adc) that bind to flt3 proteins
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
US11091546B2 (en) 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
CN105949277B (zh) * 2015-05-05 2019-03-01 成都永泰诺科技有限公司 一种抗肿瘤化合物及其用途
CN107029242A (zh) 2015-11-03 2017-08-11 财团法人工业技术研究院 抗体药物复合物及其制造方法
KR102891788B1 (ko) 2016-02-04 2025-11-26 더 스크립스 리서치 인스티튜트 인간화 항-cd3 항체, 접합체 및 이의 용도
PE20231050A1 (es) 2016-03-02 2023-07-11 Eisai Randd Man Co Ltd Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
CN109843919A (zh) 2016-03-25 2019-06-04 西雅图基因公司 用于制备聚乙二醇化的药物-接头及其中间体的方法
EP3529268B1 (en) 2016-10-19 2025-02-26 The Scripps Research Institute Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
PE20191716A1 (es) 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
KR102648564B1 (ko) 2017-03-24 2024-03-19 씨젠 인크. 글루쿠로니드 약물-링커의 제조 공정 및 그 중간물
MX2020004691A (es) 2017-11-07 2020-08-20 Regeneron Pharma Enlazadores hidrofilicos para conjugados anticuerpo-farmaco.
KR102762352B1 (ko) * 2017-11-30 2025-02-05 씨젠 인크. 약물 링커 화합물의 제조방법
MX2020010104A (es) 2018-03-29 2020-11-06 Ambrx Inc Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado.
EP3807644A4 (en) 2018-06-12 2022-07-06 Angiex, Inc. ANTIBODY-OLIGONUCLEOTIDE CONJUGATES
CN109232712B (zh) * 2018-08-21 2021-08-03 联宁（苏州）生物制药有限公司 一种用于抗体药物偶联物的中间体的制备方法
CN119264211A (zh) 2018-08-27 2025-01-07 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
MX2021002301A (es) 2018-08-28 2021-04-28 Ambrx Inc Bioconjugados de anticuerpo-foliato anti-cd3 y sus usos.
CA3128081A1 (en) 2019-02-12 2020-08-20 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
MX2021010254A (es) 2019-02-27 2021-09-21 Angiex Inc Conjugados de anticuerpo-farmaco que comprenden anticuerpos anti-tm4sf1 y metodos de uso de los mismos.
BR112022001054A2 (pt) * 2019-08-21 2022-03-15 Kalvista Pharmaceuticals Ltd Inibidores enzimáticos
EP4017542A1 (en) 2019-10-04 2022-06-29 Tae Life Sciences Antibody compositions comprising fc mutations and site-specific conjugation properties
WO2021173889A1 (en) 2020-02-26 2021-09-02 Ambrx, Inc. Uses of anti-cd3 antibody folate bioconjugates
US20230022596A1 (en) * 2021-06-18 2023-01-26 Clarence Hurt Neoantigen-eliciting antibody drug conjugates for the immunotherapy of cancer
WO2023000171A1 (zh) * 2021-07-20 2023-01-26 浙江新码生物医药有限公司 一种含有抗her2-药物偶联物的冻干组合物、冻干制剂及其制备方法和用途
CN118119409A (zh) 2021-09-03 2024-05-31 东丽株式会社 癌的治疗和/或预防用药物组合物
WO2024077277A1 (en) 2022-10-07 2024-04-11 Ambrx, Inc. Drug linkers and antibody conjugates thereof
JP2026504093A (ja) 2023-01-16 2026-02-03 アンブレツクス・インコーポレイテツド 抗ｃｄ７０抗体薬物コンジュゲート
WO2024178310A1 (en) 2023-02-23 2024-08-29 Ambrx, Inc. Trop2-directed antibody-drug conjugates and uses thereof
WO2024241086A1 (en) 2023-05-24 2024-11-28 Ambrx, Inc. Pegylated bovine interferon lambda and methods of use thereof
AU2024304180A1 (en) 2023-06-13 2026-01-08 Adcentrx Therapeutics, Inc. Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins
AU2024329469A1 (en) 2023-08-22 2026-04-09 Ambrx, Inc. Anti-psma adc conjugate compositions and methods of use thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN118754934B (zh) * 2024-06-05 2025-02-07 浙江新码生物医药有限公司 一种用于制备药物偶联物的毒素衍生物
WO2025264533A1 (en) 2024-06-17 2025-12-26 Adcentrx Therapeutics Inc. Methods and compositions related to antibody drug conjugates (adcs) that bind steap-1 proteins
WO2025262641A1 (en) 2024-06-19 2025-12-26 Pheon Therapeutics Ltd Antibody drug conjugates that bind cdcp1 and uses thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
ATE66469T1 (de) 1985-01-14 1991-09-15 Neorx Corp Metall-radionuklid markiertes protein fuer diagnose und therapie.
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5831002A (en) 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
US6034065A (en) * 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US5635483A (en) * 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5599902A (en) * 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
WO1999045026A1 (en) 1998-03-05 1999-09-10 Chiron Corporation Method for increasing the serum half-life of a biologically active molecule
CN1762990A (zh) * 1999-06-08 2006-04-26 拉卓拉药物公司 包含氨基氧基的化合价平台分子
US6323315B1 (en) * 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
AU7476101A (en) * 2000-06-16 2001-12-24 Department Of Radiation Oncolo Biotin derivatives
WO2002085923A2 (en) 2001-04-19 2002-10-31 The Scripps Research Institute In vivo incorporation of unnatural amino acids
US6649402B2 (en) 2001-06-22 2003-11-18 Wisconsin Alumni Research Foundation Microfabricated microbial growth assay method and apparatus
US6737409B2 (en) 2001-07-19 2004-05-18 Hoffmann-La Roche Inc. Dolastatin 10 derivatives
CA2467242A1 (en) * 2001-11-20 2003-05-30 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
DK1545613T3 (da) * 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
CA2508939A1 (en) 2002-12-22 2004-07-15 The Scripps Research Institute Protein arrays
JP5356648B2 (ja) * 2003-02-20 2013-12-04 シアトル ジェネティックス， インコーポレイテッド 抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
MXPA06013998A (es) * 2004-06-02 2007-02-08 Hoffmann La Roche Sintesis de ester de alquilo de acido amino-alcoxi-heptanoico.
US7807619B2 (en) 2004-11-01 2010-10-05 The Regents Of The University Of California Compositions and methods for modification of biomolecules
DK1912677T3 (da) * 2005-06-20 2014-01-13 Psma Dev Company L L C PSMA-antistof-lægemiddel-konjugater
CN101400646A (zh) 2005-11-08 2009-04-01 Ambrx公司 用于修饰非天然氨基酸和非天然氨基酸多肽的促进剂
US7750116B1 (en) * 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
DK2265283T3 (da) * 2008-03-18 2014-10-20 Seattle Genetics Inc Auristatin-lægemiddel-linker-konjugater
US8309093B2 (en) * 2009-03-06 2012-11-13 Agensys, Inc. Antibody drug conjugates (ADC) that bind to 24P4C12 proteins
RU2583270C2 (ru) * 2009-04-01 2016-05-10 Дженентек, Инк. АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US8521087B2 (en) 2009-07-15 2013-08-27 Lg Electronics Inc. System and method for cognitive radio transmission
JP2013505944A (ja) * 2009-09-24 2013-02-21 シアトル ジェネティックス， インコーポレイテッド Ｄｒ５リガンド薬物結合体
EP2501711B1 (en) * 2009-11-16 2014-01-08 Centre National De La Recherche Scientifique CNRS Compounds and methods for purifying peptides produced by solid phase peptide synthesis
MX393973B (es) 2011-05-08 2025-03-24 Legochem Biosciences Inc Conjugados de proteína-agente activo y método para su preparación.
CN110078789A (zh) * 2011-05-27 2019-08-02 Ambrx 公司 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途
KR102356286B1 (ko) * 2011-05-27 2022-02-08 암브룩스, 인코포레이티드 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도

Also Published As

Publication number Publication date
CN110078788B (zh) 2021-08-06
US10954270B2 (en) 2021-03-23
CO6811816A2 (es) 2013-12-16
CR20130667A (es) 2014-03-12
NZ618079A (en) 2016-04-29
JP7638942B2 (ja) 2025-03-04
IL229505A (en) 2017-10-31
CN113527414A (zh) 2021-10-22
AU2018203639A1 (en) 2018-06-14
AU2018203639B2 (en) 2020-05-14
IL229505A0 (en) 2014-01-30
CL2013003406A1 (es) 2014-07-25
US20220411469A1 (en) 2022-12-29
CA2837586C (en) 2018-12-11
KR102179369B1 (ko) 2020-11-16
IL254879A0 (en) 2017-12-31
EP2714684B1 (en) 2018-09-05
PH12013502461A1 (en) 2017-08-09
US20160052966A1 (en) 2016-02-25
KR20210106023A (ko) 2021-08-27
ES2690993T3 (es) 2018-11-23
KR102356286B1 (ko) 2022-02-08
ECSP13013115A (es) 2014-06-30
GT201300295A (es) 2014-11-24
KR20190115109A (ko) 2019-10-10
IL274204B (en) 2022-03-01
JP2023002671A (ja) 2023-01-10
AU2012262560B2 (en) 2016-06-09
CN110078788A (zh) 2019-08-02
EP3470413A2 (en) 2019-04-17
KR102030856B1 (ko) 2019-10-10
JP2020147587A (ja) 2020-09-17
CN110078787A (zh) 2019-08-02
AU2016204454A1 (en) 2016-07-21
US11420999B2 (en) 2022-08-23
EA201391756A1 (ru) 2014-05-30
EP2714684A1 (en) 2014-04-09
JP2014516050A (ja) 2014-07-07
NI201300130A (es) 2014-12-22
EP2714684A4 (en) 2015-04-08
KR20140028073A (ko) 2014-03-07
US20180009845A1 (en) 2018-01-11
MX2013013683A (es) 2014-01-08
ZA201309654B (en) 2016-08-31
BR112013030372A2 (pt) 2016-08-30
EP3470413A3 (en) 2019-08-07
IL274204A (en) 2020-06-30
AU2012262560A1 (en) 2013-05-09
JP6781721B2 (ja) 2020-11-04
PE20140784A1 (es) 2014-07-03
CN103717595A (zh) 2014-04-09
DK2714684T3 (en) 2018-11-26
AU2016204454B2 (en) 2018-03-01
KR20200128601A (ko) 2020-11-13
AU2020217337A1 (en) 2020-08-27
MX359217B (es) 2018-09-19
AU2020217337B2 (en) 2022-11-17
CA2837586A1 (en) 2012-12-06
US9796754B2 (en) 2017-10-24
WO2012166560A1 (en) 2012-12-06
IL254879B (en) 2020-05-31
JP2024170587A (ja) 2024-12-10
JP2018109033A (ja) 2018-07-12
US20210277056A1 (en) 2021-09-09

Similar Documents

Publication Publication Date Title
JP7638942B2 (ja) 非天然アミノ酸結合ドラスタチン誘導体を含有する組成物、それを用いた方法、およびその使用
JP6215197B2 (ja) 非天然アミノ酸結合ドラスタチン誘導体を含有する化合物、またはその塩
JP6425650B2 (ja) 前立腺特異的膜抗原抗体薬物複合体
HK40007145A (en) Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
HK1196613B (en) Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
HK1196613A (en) Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
HK1196612B (en) Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
HK1196612A (en) Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160329

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170501

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180216

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20180216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180216

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180307

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20180518

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190627

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190902

R150 Certificate of patent or registration of utility model

Ref document number: 6581774

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250